Skip to main content

Search

POCT and Translation Clinical Biochemistry

Research aim: My research focus is to improve patient outcomes by developing and implementing laboratory methods that optimally support both patients and clinical colleagues in everyday healthcare practice. The goal is to generate knowledge and solutions that can be directly translated into better diagnostics, more precise treatment, and increased patient involvement.

My research centers on three main areas:

 

1. Point-of-Care Testing (POCT):

Development, implementation, and evaluation of POCT in various settings – hospitals, general practice, nursing homes, and in patients’ own homes – with a particular emphasis on patient engagement in self-testing.

 

2. Biomarkers and advanced analyses:

Identification and application of biomarkers for:

  • Screening (e.g., colorectal cancer, prenatal diagnostics of chromosomal abnormalities, preeclampsia).
  • Risk assessment and stratification of acutely ill medical and surgical patients (triage) with the aim of optimizing patient flow in the emergency department (FAM).
  • TDM (therapeutic drug monitoring) for biological drugs, drug of abuse and chemotherapy.

 

3. Pathophysiological understanding and disease development:

We work from the hypothesis that a significant cause of both acute and chronic disease is frailty, which is partly triggered by underlying dysmetabolism leading to oxidative stress and chronic inflammation. Therefore, we aim to develop biomarkers for frailty and test them in the diagnostics of acute kidney injury as well as in the detection of long-term sequelae.

With this approach, I aim to bridge laboratory research and clinical practice – with the overarching goal of developing diagnostic tools and strategies that improve patient care, increase the precision of risk assessment, and strengthen patients’ active role in managing their own health.

 

Projects

POCT home self-testing for monitoring

  1. Develop of POCT TDM for biological drugs.
  2. Development of a proof of concept setup.

 

Available cohorts and infrastructures

  • acute cohort from EMD, Hillerød Hospital, 1000 patients.

 

Collaborators

  • Anders Hay-Schmidt, Professor MSO, Odontologisk institut, Københavns Universitet.
  • Hanne Vestergaard Hanne Vestergaard, Cheflæge, ph.d., MPG, Hæmatologisk Afdeling X, OUH.
  • Thomas Lund, leder af Hæmatologisk afsnit, Medicinsk afd, Vejle Sygehus.
  • Ion Trærup -Andersen, Professor Klinisk Farmakologi, Bispebjerg Hospital.
  • Mikkel Bring Christensen, Professor Klinisk Farmakologi, Bispebjerg Hospital.

 

Selected publications

POCT
  • Home self-testing of complete blood counts in patients with breast cancer during chemotherapy: A proof-of-concept cohort study in e-oncology.Friis-Hansen L, Bjørck PJ, Hartvig D, Andresen S, Nielsen BH, Hansen C, Nistrup A, Hundewadt K, Holländer NH. Acta Oncol. 2024;63:718-727. doi: 10.2340/1651-226X.2024.41050.

  • A nationwide analytical and clinical evaluation of 44 rapid antigen tests for SARS-CoV-2 compared to RT-qPCR.Schneider UV, Forsberg MW, Leineweber TD, Jensen CB, Ghathian K, Agergaard CN, Mortensen KK, Cohen A, Jørgensen CS, Larsen H, Hansen MB, Saleme U, Koch A, Kirkby NS, Kallemose T, Schaadt ML, Jensen FH, Jørgensen RL, Ma CMG, Steenhard N, Knudsen JD, Lisby JG; National Danish RAT testing group. J Clin Virol. 2022;153:105214. doi: 10.1016/j.jcv.2022.105214.

  • The HemoScreen hematology point-of-care device is suitable for rapid evaluation of acute leukemia patients.Kristian Kur D, Thøgersen D, Kjeldsen L, Friis-Hansen L. Int J Lab Hematol. 2021;43:52-60. doi: 10.1111/ijlh.13330.
 
Biomarkers and advanced analyses
  • Unpacking KDIGO Guidelines: Prioritizing and Applying Exposures and Susceptibilities for AKI in Clinical Practice.Wetterstrand VJR, Kallemose T, Larsen JJ, Friis-Hansen LJ, Brandi L.J Clin Med. 2025;14:2572. doi: 10.3390/jcm14082572.

  • Lower Bone Mineral Density in Female Elite Athletes With Menstrual Dysfunction From Mixed Sports.Stangerup I, Melin AK, Lichtenstein M, Friis-Hansen L, Jørgensen NR, Schjerling P, Kjaer M, Mertz KH. Transl Sports Med. 2025:4969624. doi: 10.1155/tsm2/4969624.

  • Plasma neutrophil gelatinase-associated lipocalin as a single test rule out biomarker for acute kidney injury: A cross-sectional study in patients admitted to the emergency department.Wetterstrand VJR, Schultz M, Kallemose T, Torre A, Larsen JJ, Friis-Hansen L, Brandi L. PLoS One. 2025 Jan 10;20(1):e0316897. doi: 10.1371/journal.pone.0316897.

  • The baseline fecal microbiome differs in patients with and without anastomotic leakage after colorectal cancer surgery.Jørgensen AB, Almer L, Samaniego Castruita JA, Pedersen MS, Kirkby NS, Jensen EA, Alfaro-Núñez A, Friis-Hansen L, Brandstrup B. Heliyon. 2024;10:e40616. doi: 10.1016/j.heliyon.2024.e40616.

  • Exploring free pregnancy associated plasma protein a (fPAPP-A) as a biomarker in early pregnancy.Petersen JF, Tiittanen V, Wittfooth S, Løkkegaard E, Friis-Hansen LJ. Pract Lab Med. 2024;42:e00428. doi: 10.1016/j.plabm.2024.e00428.
Lennart Jan Friis-Hansen

Visiting Researcher

More information

Last Updated 22.04.2026